Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?

International Journal of Clinical Pharmacy · Published 2026-07-24 · DOI 10.1007/s11096-026-02192-2

Free full text

Authors (19)

Edel Burton, Kate E. Coakley, Siobhán Gaynor, Mei McDonagh, Christopher Palmer, Laura J. Sahm, Seamus O’Reilly, Biologics Impact on Patient Care and Treatment (Bio ImPAcT) Consortium, Ann Doherty, Colleen Dube, Clare Fitzell, Patricia Heckmann, Siobhán Lucey, Siobhán Masterson, Anne Mooney, Éilis J. O’Reilly, Mohamad M. Saab, Emma Wallace, Bjorn Wettermark

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Burton, E., Coakley, K., Gaynor, S., et al. (2026). Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-026-02192-2

Related articles

• Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability · BioDrugs · 2025 · Cites or is cited by this article
• Perspectives on shared decision making related to medications from patients with multiple long-term conditions transitioning from hospital to home: a qualitative study · International Journal of Clinical Pharmacy · 2026 · Same journal
• Development of a real-world, therapeutic drug monitoring–informed model to predict teicoplanin daily dose in pediatric intensive care unit patients with bacterial infections · International Journal of Clinical Pharmacy · 2026 · Same journal
• Comment on “evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation” · International Journal of Clinical Pharmacy · 2026 · Same journal
• Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System · International Journal of Clinical Pharmacy · 2026 · Same journal
• Patient perspectives on atrial fibrillation management and pharmacist roles in outpatient clinics: a qualitative study · International Journal of Clinical Pharmacy · 2026 · Same journal
• Active surveillance and risk prediction of piperacillin/tazobactam‑associated hypokalaemia: development and external validation of a clinical nomogram · International Journal of Clinical Pharmacy · 2026 · Same journal
• Consumers’ experiences and perspectives on reporting adverse drug reactions using digital tools: a qualitative study · International Journal of Clinical Pharmacy · 2026 · Same journal
• Grounding clinical supervision in advanced pharmacy practice: a new conceptual model · International Journal of Clinical Pharmacy · 2026 · Same journal
• A multi-method study of unlicensed medicine risk assessment: a cross-sectional survey of pharmacy procurement leads and policy analysis across NHS trusts in England · International Journal of Clinical Pharmacy · 2026 · Same journal